Menu
/REGISTER
Montecito
Nixon Peabody
Pac Premier
Loading...
You are here:  Home  >  'Praluent'
Latest

Judge rules for Amgen in patent dispute over Repatha competitor

By   /  Monday, February 25th, 2019  /  Biotech, East Ventura County, Latest news, Law, Technology  /  Comments Off on Judge rules for Amgen in patent dispute over Repatha competitor

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen cuts cholesterol drug price by 60 percent

By   /  Wednesday, October 24th, 2018  /  Latest news  /  Comments Off on Amgen cuts cholesterol drug price by 60 percent

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen stock stable despite end of drug ban

By   /  Friday, October 13th, 2017  /  Latest news  /  Comments Off on Amgen stock stable despite end of drug ban

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen lawsuit over cholesterol drug will get new trial

By   /  Thursday, October 5th, 2017  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on Amgen lawsuit over cholesterol drug will get new trial

An Amgen lawsuit against a competing cholesterol drug will get a new trial but sales of the drug will be allowed in the U.S. until a decision is rendered. A federal court of appeals judge threw out a ban on the sale of Praluent, manufactured by New York-based Regeneron Pharmaceuticals and French biotech company Sanofi Read More →

Read More →
Latest

Patent ruling in favor of Amgen has shares skyrocketing

By   /  Friday, January 13th, 2017  /  Central Coast Health Watch, Latest news, Tri-County Public Companies  /  Comments Off on Patent ruling in favor of Amgen has shares skyrocketing

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen shares climb after judge upholds Repatha patents

By   /  Friday, January 6th, 2017  /  Central Coast Health Watch, Latest news, Law  /  Comments Off on Amgen shares climb after judge upholds Repatha patents

A ruling in a patent law case regarding a new anti-cholesterol drug involving Thousand Oaks biotech giant Amgen has skyrocketed Amgen shares. Amgen filed a patent infringement lawsuit against Sanofi and Regeneron in the U.S. District Court of Delaware in October 2014 to block the development and sale of the drug Praluent, which was developed Read More →

Read More →